Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Revenue of Bausch + Lomb Corporation (BLCO)
Revenue in 2023 (TTM): $4.15 B
According to Bausch + Lomb Corporation's latest financial reports the company's current revenue (TTM) is $4.15 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Bausch + Lomb Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $4.15 B | $2.5 B | $601 M | $-166,000,000 | $-260,000,000 |
| 2022 | $3.77 B | $2.25 B | $457 M | $73 M | $15 M |
| 2021 | $3.77 B | $2.3 B | $785 M | $318 M | $182 M |
| 2020 | $3.41 B | $2.13 B | $750 M | $290 M | $-17,000,000 |
| 2019 | $3.78 B | $2.45 B | $1 B | $399 M | $298 M |
| 2018 | $3.67 B | $2.35 B | $932 M | $417 M | $710 M |